Une étude pour évaluer la sécurité, la tolérabilité et l'efficacité à long terme du Balinatunfib chez les participants atteints de la maladie de Crohn ou de colite ulcéreuse (SPECIFI-IBD-LTS)
Étude multinationale et multicentrique de prolongation visant à évaluer l'innocuité, la tolérabilité et l'efficacité à long terme du Balinatunfib chez les adultes atteints de la maladie de Crohn ou de colite ulcéreuse
LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week treatment period (on balinatunfib or placebo) in the parent studies, SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822), respectively.
-
The primary objective of this study is to assess the long-term safety and tolerability of different doses of balinatunfib in participants with CD or UC, as measured by the number and percentage of participants with CD or UC with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the study period.
-
The study will consist of 2 independent cohorts through the study given the distinct nature of each disease:
- CD Cohort: comprised of CD participants enrolled from SPECIFI-CD (DRI18212).
- UC Cohort: comprised of UC participants enrolled from SPECIFI-UC (DRI17822).
-
The study will consist of the following study periods for each cohort:
-
A Double-Blind (DB) treatment period of up to 104 weeks for eligible participants from the DB maintenance phases of the respective parent studies.
-
An Open-Label (OL) treatment period of up to 104 weeks for:
- Eligible participants from either the DB or OL periods of the parent studies,
- Eligible participants who meet escape criteria at any time during the DB period of the LTS19689.
-
A 2-week follow-up period following the End of Treatment (EOT). The study duration will be up to 107 weeks, with the treatment duration up to 104 weeks.
-
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Buenos Aires, Argentine, 1061
- Investigational Site Number : 0320001
-
-
-
-
-
Gorna Oryahovitsa, Bulgarie, 5100
- Investigational Site Number : 1000001
-
-
-
-
Reg Metropolitana de Santiago
-
Santiago, Reg Metropolitana de Santiago, Chili, 8331143
- Investigational Site Number : 1520010
-
Santiago, Reg Metropolitana de Santiago, Chili, 7500010
- Investigational Site Number : 1520016
-
Santiago, Reg Metropolitana de Santiago, Chili, 8380456
- Investigational Site Number : 1520012
-
-
-
-
-
Guangzhou, Chine, 510080
- Investigational Site Number : 1560002
-
Shanghai, Chine, 200120
- Investigational Site Number : 1560032
-
-
-
-
Milano
-
Milan, Milano, Italie, 20132
- Investigational Site Number : 3800002
-
-
-
-
-
Olomouc, Tchéquie, 779 00
- Investigational Site Number : 2030001
-
-
-
-
Texas
-
Southlake, Texas, États-Unis, 76092
- Texas Digestive Disease Consultants - Southlake- Site Number : 8400005
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
-
Participants with Crohn's Disease (CD) or ulcerative colitis (UC) who completed treatment at Week 52 of the SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822) studies, respectively:
-
Participants with CD
-
who complete double-blinded treatment at Week 52 of SPECIFI-CD (DRI18212) study;
-
who complete open label treatment and achieve the appropriate outcomes at Week 52 of SPECIFI-CD (DRI18212) study.
OR
-
-
Participants with UC
- who complete double-blinded treatment at Week 52 of SPECIFI-UC (DRI17822) study;
- who complete open label treatment and achieve the appropriate outcomes at Week 52 of the SPECIFI-UC (DRI17822) study.
-
-
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding
Exclusion Criteria:
- Participants with CD who develop a new medical condition precluding participation as described in Exclusion criteria of SPECIFI-CD (DRI18212) clinical trial protocol.
- Participants with UC who develop a new medical condition precluding participation as described in Exclusion criteria of SPECIFI-UC (DRI17822) clinical trial protocol.
- Participants who developed a new medical condition or a change in status of an established medical condition which (per Investigator's medical judgment) would adversely affect the participation in this study or would require permanent IMP discontinuation.
- Participants who permanently discontinued IMP during the parent study or temporarily discontinued IMP for more than 14 consecutive calendar days by the time of Day 1 of LTS19689.
- Participants who, during their participation in the parent study, developed an adverse event (AE) or a serious adverse event (SAE) deemed related to balinatunfib, which in the opinion of the Investigator could indicate that continued treatment with balinatunfib may present an unreasonable risk for the participant.
- Participants who in the parent study had documented nonadherence to IMP or to standard therapies for CD or UC, or who used a prohibited medication concomitant with IMP or during a temporary IMP discontinuation period.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: CD cohort: balinatunfib dose regimen 1
Participants will receive balinatunfib dose regimen 1 |
Pharmaceutical form:Tablet -Route of administration:Oral
Autres noms:
|
|
Expérimental: CD cohort: balinatunfib dose regimen 2
Participants will receive balinatunfib dose regimen 2 |
Pharmaceutical form:Tablet -Route of administration:Oral
Autres noms:
|
|
Expérimental: CD cohort: balinatunfib dose regimen 3
Participants will receive balinatunfib dose regimen 3 |
Pharmaceutical form:Tablet -Route of administration:Oral
Autres noms:
|
|
Comparateur placebo: CD cohort: Placebo
Participants will receive balinatunfib-matching placebo |
Pharmaceutical form:Tablet -Route of administration:Oral |
|
Expérimental: UC cohort: balinatunfib dose regimen 1
Participants will receive balinatunfib dose regimen 1 |
Pharmaceutical form:Tablet -Route of administration:Oral
Autres noms:
|
|
Expérimental: UC cohort: balinatunfib dose regimen 2
Participants will receive balinatunfib dose regimen 2 |
Pharmaceutical form:Tablet -Route of administration:Oral
Autres noms:
|
|
Expérimental: UC cohort: balinatunfib dose regimen 3
Participants will receive balinatunfib dose regimen 3 |
Pharmaceutical form:Tablet -Route of administration:Oral
Autres noms:
|
|
Comparateur placebo: UC cohort: Placebo
Participants will receive balinatunfib-matching placebo |
Pharmaceutical form:Tablet -Route of administration:Oral |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Nombre de participants atteints de la maladie de Crohn présentant des événements indésirables émergents du traitement (EIET), des événements indésirables graves (EIG) et des événements indésirables d'intérêt spécial (EIIS)
Délai: Jusqu'à la fin de l'étude (environ 106 semaines)
|
Jusqu'à la fin de l'étude (environ 106 semaines)
|
|
Nombre de participants atteints de colite ulcéreuse présentant des événements indésirables émergents du traitement (EIET), des événements indésirables graves (EIG) et des événements indésirables d'intérêt particulier (EAIP)
Délai: Jusqu'à la fin de l'étude (environ 106 semaines)
|
Jusqu'à la fin de l'étude (environ 106 semaines)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of participants with Crohn's Disease in endoscopic remission based on simple endoscopic score for Crohn's disease (SES-CD)
Délai: Week 52
|
Endoscopic remission is defined as SES-CD ≤4 points (SES CD ≤2 points for isolated ileal disease) and a SES-CD decrease ≥2 points with no SES-CD subscore >1 point from baseline. The SES-CD evaluates 4 endoscopic items (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease. |
Week 52
|
|
Proportion of participants with Crohn's Disease in endoscopic remission based on simple endoscopic score for Crohn's disease (SES-CD)
Délai: Week 104
|
Endoscopic remission is defined as SES-CD ≤4 points (SES CD ≤2 points for isolated ileal disease) and a SES-CD decrease ≥2 points with no SES-CD subscore >1 point from baseline. The SES-CD evaluates 4 endoscopic items (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease. |
Week 104
|
|
Proportion of participants with Crohn's Disease in clinical remission based on Crohn's disease activity index (CDAI)
Délai: Week 52
|
Clinical remission is defined as CDAI <150. The CDAI score is composed of eight items: 3 of them (abdominal pain, stool frequency and general well-being) completed by the participant and the others (use of anti-diarrheal medications, extraintestinal complications, palpable abdominal mass, hematocrit levels, and body weight) assessed and reported by the clinician. The CDAI is derived from summing up the weighted individual scores of eight items. Scores on the CDAI scale range from 0 to 600, with higher scores indicating more severe disease. |
Week 52
|
|
Proportion of participants with Crohn's Disease in clinical remission based on Crohn's disease activity index (CDAI)
Délai: Week 104
|
Clinical remission is defined as CDAI <150. The CDAI score is composed of eight items: 3 of them (abdominal pain, stool frequency and general well-being) completed by the participant and the others (use of anti-diarrheal medications, extraintestinal complications, palpable abdominal mass, hematocrit levels, and body weight) assessed and reported by the clinician. The CDAI is derived from summing up the weighted individual scores of eight items. Scores on the CDAI scale range from 0 to 600, with higher scores indicating more severe disease. |
Week 104
|
|
Proportion of participants with ulcerative colitis in clinical remission based on modified Mayo Score (mMS)
Délai: Week 52
|
Clinical remission by modified Mayo score (mMS) is defined as a mMS score of 0 to 2, including stool frequency (SF) of 0 or 1, rectal bleeding (RB) subscore of 0, and centrally read modified Mayo Endoscopic Subscore [mMES] of 0 or 1 (score of 1 modified to exclude friability).Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity |
Week 52
|
|
Proportion of participants with ulcerative colitis in clinical remission based on modified Mayo Score (mMS)
Délai: Week 104
|
Clinical remission by modified Mayo score (mMS) is defined as a mMS score of 0 to 2, including stool frequency (SF) of 0 or 1, rectal bleeding (RB) subscore of 0, and centrally read modified Mayo Endoscopic Subscore [mMES] of 0 or 1 (score of 1 modified to exclude friability).Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity |
Week 104
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LTS19689
- 2025-522511-42 (Identificateur de registre: CTIS)
- U1111-1321-1765 (Identificateur de registre: WHO ICTRP)
- 2025 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .